Integra Lifesciences Stake Corp (IART) Shares Obtained by First Trust Advisors LP

Integra Lifesciences Stake Corp (IART) Shares Obtained by First Trust Advisors LP

First Trust Advisors LP raised its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 472.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 389,720 shares of the life sciences company’s stock after acquiring an additional 321,619 shares during the quarter. First Trust Advisors LP owned approximately 0.46% of Integra Lifesciences worth $25,671,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Zeke Capital Advisors LLC acquired a new stake in shares of Integra Lifesciences during the second quarter worth $204,000. We Are One Seven LLC acquired a new stake in shares of Integra Lifesciences during the third quarter worth $211,000. Eagle Boston Investment Management Inc. acquired a new stake in shares of Integra Lifesciences during the second quarter worth $223,000. World Asset Management Inc acquired a new stake in shares of Integra Lifesciences during the second quarter worth $261,000. Finally, LS Investment Advisors LLC raised its holdings in shares of Integra Lifesciences by 99.3% during the second quarter. LS Investment Advisors LLC now owns 4,276 shares of the life sciences company’s stock worth $275,000 after purchasing an additional 2,130 shares during the period. Hedge funds and other institutional investors own 84.82% of the company’s stock.

A number of analysts have weighed in on the stock. Cantor Fitzgerald reissued a “hold” rating and set a $59.00 target price on shares of Integra Lifesciences in a report on Wednesday, July 25th. BidaskClub cut shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, July 27th. BTIG Research raised shares of Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 target price on the stock in a report on Thursday, July 26th. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Integra Lifesciences in a report on Friday, August 17th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $61.00.

IART stock opened at $53.88 on Tuesday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 2.08 and a current ratio of 3.20. Integra Lifesciences Holdings Corp has a fifty-two week low of $45.96 and a fifty-two week high of $67.50. The stock has a market capitalization of $4.57 billion, a P/E ratio of 27.77, a PEG ratio of 1.69 and a beta of 0.76.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.59. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The business had revenue of $365.85 million for the quarter, compared to analysts’ expectations of $367.89 million. During the same quarter last year, the company earned $0.45 EPS. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, research analysts forecast that Integra Lifesciences Holdings Corp will post 2.39 earnings per share for the current fiscal year.

In other Integra Lifesciences news, insider Jeffrey Mosebrook sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $62.42, for a total transaction of $62,420.00. Following the transaction, the insider now owns 3,085 shares of the company’s stock, valued at approximately $192,565.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Richard E. Caruso sold 46,676 shares of the firm’s stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $8,475,927.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,592 shares of company stock worth $3,573,584. 5.10% of the stock is owned by corporate insiders.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: What are the benefits of a balanced fund?

Related posts

Leave a Comment